Phase 2 Study of AUR103 Calcium in Advanced Neuroendocrine Tumours Initiated
AUR103 calcium is being evaluated in Phase 2 study for efficacy and safety in advanced neuroendocrine tumors.
Company
Pharmaceutical intelligence for AUR103 Pharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.